NASDAQ:SAGESAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAGE stock has increased by 1.7% and is now trading at $43.01. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SAGE Therapeutics.

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for SAGE Therapeutics.

SAGE Therapeutics Inc (NASDAQ:SAGE) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.17) by $0.73. The biopharmaceutical company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.81 million. SAGE Therapeutics had a negative net margin of 7,406.75% and a negative return on equity of 63.13%. SAGE Therapeutics's quarterly revenue was up 391.6% on a year-over-year basis. During the same quarter last year, the firm posted ($3.37) earnings per share. View SAGE Therapeutics' earnings history.

18 brokers have issued twelve-month price objectives for SAGE Therapeutics' shares. Their forecasts range from $28.00 to $263.00. On average, they anticipate SAGE Therapeutics' share price to reach $82.11 in the next twelve months. This suggests a possible upside of 90.9% from the stock's current price. View analysts' price targets for SAGE Therapeutics.

News articles about SAGE stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SAGE Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about SAGE Therapeutics.

Some companies that are related to SAGE Therapeutics include Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Legend Biotech (LEGN) and Mirati Therapeutics (MRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), salesforce.com (CRM) and Johnson & Johnson (JNJ).

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View institutional ownership trends for SAGE Therapeutics.

SAGE stock was acquired by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas. View insider buying and selling activity for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $43.01.

SAGE Therapeutics has a market capitalization of $2.23 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.

The official website for SAGE Therapeutics is www.sagerx.com.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]